 |
|
Where do we stand on human diabetic nephropathy?
Dae Ryong Cha
Kidney Res Clin Pract. 2013;32(3):93-95. Published online 2013 Aug 31 DOI: https://doi.org/10.1016/j.krcp.2013.07.007
|
|
Citations to this article as recorded by
 Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects
Cara H. Nelson, Kim Etchevers, Saili Yi, David Breckenridge, Mischa Hepner, Uptal Patel, John Ling, Anita Mathias
Clinical Pharmacokinetics.2020; 59(9): 1109. CrossRef Effects of Selonsertib in Patients with Diabetic Kidney Disease
Glenn M. Chertow, Pablo E. Pergola, Fang Chen, Brian J. Kirby, John S. Sundy, Uptal D. Patel
Journal of the American Society of Nephrology.2019; 30(10): 1980. CrossRef Diabetic Retinopathy and Clinical Parameters Favoring the Presence of Diabetic Nephropathy could Predict Renal Outcome in Patients with Diabetic Kidney Disease
Chi-Chih Hung, Hugo You-Hsien Lin, Daw-Yang Hwang, I-Ching Kuo, Yi-Wen Chiu, Lee-Moay Lim, Shang-Jyh Hwang, Hung-Chun Chen
Scientific Reports.2017;[Epub] CrossRef
|